Houle Steeve, Papez Martin D, Ferazzini Mara, Hollenberg Morley D, Vergnolle Nathalie
Department of Pharmacology and Therapeutics, Faculty of Medicine, Canadian Institutes of Health Proteinases and Inflammation Network, Mucosal Inflammation Research Group, University of Calgary, Alberta, Canada.
Br J Pharmacol. 2005 Nov;146(5):670-8. doi: 10.1038/sj.bjp.0706371.
1 We evaluated a potential role for proteinase-activated receptor 4 (PAR(4)) in a rodent paw inflammation model, with a focus on two main features of inflammation: (1) oedema and (2) granulocyte recruitment. 2 A PAR(4) antagonist (Pepducin P4pal-10; palmitoyl-SGRRYGHALR-NH(2)) reduced both the oedema and granulocyte recruitment induced by a localized administration of carrageenan in the rat hind paw, pointing to a key role for PAR(4) in this inflammation model. 3 Further, intraplantar injection in the mouse hind paw of a PAR(4) agonist (AYPGKF-NH(2)), but not its standard PAR(4)-inactive peptide control (YAPGKF-NH(2)), caused an inflammatory reaction characterized by oedema (increased paw thickness) and granulocyte recruitment (increased paw myeloperoxidase activity). The PAR(4) agonist-induced effects were inhibited in mice pretreated with pepducin P4pal10. 4 These PAR(4) agonist-mediated effects were not affected by pretreatment with inhibitors of either NO production or prostaglandin release (L-NAME and indomethacin, respectively). 5 However, selective immuno-depletion of neutrophils significantly reduced PAR(4) agonist-induced oedema formation. 6 Moreover, AYPGKF-NH(2)-induced oedema was also reduced by pretreatment with either a kinin B(2) receptor antagonist (icatibant) or a tissue or plasma kallikrein inhibitor (FE999024 and FE999026, respectively), but not with a kinin B(1) receptor antagonist (SSR240612). 7 We conclude: (1) that PAR(4) plays an important role in the inflammatory response as it mediates some of the hallmarks of inflammation and (2) that PAR(4)-mediated oedema is dependent on the recruitment of neutrophils and components of the kallikrein-kinin system.
1我们在啮齿动物爪部炎症模型中评估了蛋白酶激活受体4(PAR(4))的潜在作用,重点关注炎症的两个主要特征:(1)水肿和(2)粒细胞募集。2一种PAR(4)拮抗剂(Pepducin P4pal-10;棕榈酰-SGRRYGHALR-NH(2))减少了角叉菜胶局部注射诱导的大鼠后爪水肿和粒细胞募集,表明PAR(4)在该炎症模型中起关键作用。3此外,在小鼠后爪足底注射PAR(4)激动剂(AYPGKF-NH(2)),而非其标准的PAR(4)无活性肽对照(YAPGKF-NH(2)),会引发以水肿(爪厚度增加)和粒细胞募集(爪髓过氧化物酶活性增加)为特征的炎症反应。用Pepducin P4pal10预处理的小鼠中,PAR(4)激动剂诱导的效应受到抑制。4这些PAR(4)激动剂介导的效应不受一氧化氮产生抑制剂或前列腺素释放抑制剂(分别为L-NAME和吲哚美辛)预处理的影响。5然而,中性粒细胞的选择性免疫清除显著降低了PAR(4)激动剂诱导的水肿形成。6此外,用激肽B(2)受体拮抗剂(艾替班特)或组织或血浆激肽释放酶抑制剂(分别为FE999024和FE999026)预处理也可减少AYPGKF-NH(2)诱导的水肿,但激肽B(1)受体拮抗剂(SSR240612)则无此作用。7我们得出结论:(1)PAR(4)在炎症反应中起重要作用,因为它介导了一些炎症特征;(2)PAR(4)介导的水肿依赖于中性粒细胞的募集以及激肽释放酶-激肽系统的成分。